ReviewWorld journal of microbiology & biotechnology2026
Non canonical perspectives on AmpR mediated ampC expression in Gram negative bacteria, with particular emphasis on the potential regulatory purview of FtsZ.
Review in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β-Lactamases (BLs) are a principal cause of antimicrobial resistance in Gram-negative bacteria, hydrolysing β-lactam antibiotics and rendering them ineffective. Among these, the chromosomally encoded AmpC is unusual: unlike plasmid-borne BLs, its expression is tightly and inducibly controlled by the transcriptional regulator AmpR, which senses peptidoglycan-recycling intermediates and switches from repressor to activator under β-lactam pressure. This review re-examines AmpR not as an isolated genetic switch but as a metabolic sensor that reads the intracellular muropeptide pool and converts it into a proportionate resistance response. Building on this, we propose a conceptual FtsZ-AmpR-AmpC axis: because FtsZ orchestrates septal peptidoglycan remodelling during cell division, it shapes the very muropeptide landscape that AmpR monitors, offering an indirect route by which division dynamics may modulate AmpC induction. This is the first review to frame AmpC regulation in this way. We further note the framework's principal limitations: the FtsZ contribution remains inferential, the physiological AmpR activators are still unidentified and the AmpR-AmpC system is not conserved across all Gram-negative bacteria. Resolving these gaps through time-resolved muropeptide profiling and controlled FtsZ perturbation may reveal new, division-linked vulnerabilities for countering β-lactam resistance.
Indexed as
Identifiers
42599354What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.